Enovis Corporation (ENOV) — Analysis Summary
Enovis Corporation (ENOV) has a market cap of $1.42B with year-over-year revenue growth of +6.7%. Net margin stands at -52.7%. The stock trades at a P/E ratio of -1.2.
Key Takeaways
- Revenue changed +6.7% year-over-year
- Net margin of -52.7%
- P/E ratio of -1.2
Compared to other companies in the ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES sector, ENOV posted revenue growth of +6.7% and trades at a P/E of -1.2.
Enovis Corporation (ENOV)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -30.8x — earnings do not cover interest payments
Debt/EBITDA at 4.8x — elevated leverage
Operating margin at -47.0% — material operating losses
Net margin at -49.9% — significant losses
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Employees
7,802
Headquarters
WILMINGTON, DE
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.